National Institute for Health and Care Excellence

25/09/2026

1 in 7 people in the UK live with migraine, but for years many had exhausted every available treatment with little relief.

That's changing.

Since NICE recommended atogepant and rimegepant, the first migraine-prevention tablets of their kind, prescriptions have more than tripled in a year. In 2025, 22,800 people received these medicines through their GP alone.

Migraines can last days, affect work, mental health and relationships, and cost the UK economy up to £9 billion a year. These tablets work differently from older preventative treatments, targeting the chemical directly associated with migraine attacks.

🔗 Read the data story: https://www.nice.org.uk/news/articles/more-than-20-000-people-benefitting-from-innovative-migraine-pills-recommended-by-nice?utm_medium=organic&utm_source=facebook&utm_campaign=migrane_date&utm_content=graphic

18/09/2026

For 35 years, Jimi lived with sickle cell disease SS (the most severe form) experiencing constant pain, repeated hospital admissions, and complications including cardiac arrest.

After taking part in a clinical trial for CRISPR gene therapy, everything changed. Within a week, the pain that had defined his entire life was gone. He has since climbed Mount Kilimanjaro and is raising 3 children while pursuing the career he always dreamed of.

In January 2025, NICE recommended Casgevy for use in England, the first CRISPR-based gene therapy to receive NICE approval, specifically recognising its potential to reduce health inequalities, as sickle cell disease disproportionately affects people from African, Caribbean, Middle Eastern, and South Asian backgrounds.

Jimi's story shows why NICE’s approval really matters.

Read Jimi's full story and find out more about NICE's guidance: https://indepth.nice.org.uk/world-sickle-cell-day/index.html

17/09/2026

NICE recommends Enhertu for people with HER2-low advanced breast cancer.

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.

Learn more: https://www.nice.org.uk/news/articles/nice-recommends-enhertu-for-people-with-her2-low-advanced-breast-cancer?utm_medium=organic&utm_source=facebook&utm_campaign=enhertu170926

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.

11/09/2026

🎙️What if more donated organs could be saved for transplant?

Our latest podcast explores machine perfusion technology and how specialist devices can keep donated livers and lungs functioning outside the body.

Find out why NICE has recommended routine NHS access and what it could mean for transplant services: https://www.nice.org.uk/news/podcasts/second-chances-how-new-technology-is-transforming-organ-transplants?utm_medium=organic&utm_source=facebook&utm_campaign=lung_transplant_podcast_110926&utm_content=video

02/09/2026

Could your experience help shape NICE guidance?

We're recruiting professional and patient experts to contribute to our assessment of digital technologies that deliver cognitive behavioural therapy (CBT) to help manage menopause symptoms.

Apply by 24 September: https://www.nice.org.uk/guidance/indevelopment/gid-htg10848?utm_medium=organic&utm_source=linkedin&utm_campaign=expert_roles_020926&utm_content=graphic

20/08/2026

Hundreds of thousands of people with type 2 diabetes could benefit from a new weekly insulin injection after NICE recommended insulin efsitora alfa.

For some people, this could reduce the number of injections needed from 365 a year to just 52.

The treatment could make a real difference to those who rely on support to manage their insulin, including some frailer people, people with sight loss, limited hand movement, learning disabilities, or those who find the injection process difficult to follow.

Fewer injections could also mean fewer visits from carers or healthcare professionals and less disruption to day-to-day life.

Find out more 👇
https://www.nice.org.uk/news/articles/nice-recommends-weekly-insulin-jab-that-could-cut-injections-from-365-a-year-to-just-52?utm_medium=organic&utm_source=facebook&utm_campaign=insulin_t2d_200826&utm_content=graphic

20/08/2026

Artificial intelligence is already being used in many areas of health and care and its role is likely to grow in the future.

But how do people feel about it?

Our next NICE Listens dialogue will explore public views on topics such as trust, fairness, transparency and accountability when using AI in health and care.

NICE Listens helps us understand the values and priorities that matter most to the public when considering complex issues.

Find out more about the next NICE Listens conversation 👇
https://www.nice.org.uk/news/blogs/nice-listens-hearing-the-public-s-views-on-ai-in-health-and-care?utm_medium=organic&utm_source=facebook&utm_campaign=nicelistens_200826&utm_content=graphic

31/07/2026

For years, Sharon experienced symptoms of PMOS but felt they were something she simply had to live with.

In the latest NICE Talks podcast, Sharon shares her experience of living with PMOS and helping to develop NICE's new guideline alongside clinical experts.

Hear how the guideline aims to support earlier diagnosis, more personalised care and routine annual reviews for people living with the condition.

🎧Listen now:
https://www.nice.org.uk/news/podcasts/pmos-how-the-new-draft-nice-guideline-could-transform-diagnosis-and-care?utm_medium=organic&utm_source=facebook&utm_campaign=nicetalks_31_07_26&utm_content=image

23/07/2026

Gavin talks about the heart failure device that remotely monitors his heart.

23/07/2026

“I’ve got a new lease of life, and I’ve got to meet my grandson, which is the most precious gift of all.”

Gavin’s story is a powerful reminder of the difference healthtech can make when it reaches the people who need it most.

After living with heart problems for much of his life, Gavin joined a clinical trial using TriageHF technology to remotely monitor people with heart failure. The implanted device detected warning signs before Gavin had noticeable symptoms, prompting his clinical team to act quickly. That early intervention helped put him on the path to a heart transplant and, ultimately, a dramatically improved quality of life.

Importantly, the clinical trial Gavin took part in at Manchester was used by NICE to help develop its guidance on algorithm-based remote monitoring in people with cardiac implantable electronic devices.

Read Gavin’s story and find out about how healthtech can be used to improve heart failure care: https://www.nice.org.uk/news/blogs/the-device-that-raised-the-alarm-and-saved-my-life?utm_medium=organic&utm_source=facebook&utm_campaign=gavin_230726&utm_content=video

Pumping Marvellous Foundation
Manchester University NHS Foundation Trust